Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial

医学 进行性疾病 胃肠病学 表皮生长因子受体 临床研究阶段 恶心 养生 肿瘤科 临床试验 内科学 癌症 化疗
作者
Yang Liu,Yelei Guo,Zhiqiang Wu,Kaichao Feng,Chuan Tong,Yao Wang,Hanren Dai,Fengxia Shi,Qingming Yang,Weidong Han
出处
期刊:Cytotherapy [Elsevier BV]
卷期号:22 (10): 573-580 被引量:109
标识
DOI:10.1016/j.jcyt.2020.04.088
摘要

The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR is a rational target in PC. We conducted a phase I clinical trial to evaluate the safety and efficacy of autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells in patients with metastatic PC. The expression levels of EGFR on tumor cells detected by immunohistochemistry were required to be more than 50%. Sixteen patients were enrolled and received one to three cycles of the CAR T-EGFR cell infusion within 6 months (median dose of CAR T cells: 3.48 × 106/kg; range, 1.31 to 8.9 × 106/kg) after the conditioning regimen with 100 to 200 mg/m2 nab-paclitaxel and 15 to 35 mg/kg cyclophosphamide. Grade ≥3 adverse events included fever/fatigue, nausea/vomiting, mucosal/cutaneous toxicities, pleural effusion and pulmonary interstitial exudation and were reversible. Of 14 evaluable patients, four achieved partial response for 2-4 months, and eight had stable disease for 2-4 months. The median progression-free survival was 3 months (range, 4-months) from the first cycle of CAR T-EGFR cell treatment, and the median overall survival of all 14 evaluable patients was 4.9 months (range, 2.9-30 months). Decreased EGFR expression on tumor cells was observed in patients who achieved stable disease with shrinkage of metastatic lesions in the liver, and enrichment of central memory T cells in infused cells improved the clinical response. In conclusion, the treatment with CAR T-EGFR cells is safe and effective in patients with metastatic PC. This trial was registered at www.clinicaltrials.gov (identifier no: NCT01869166).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被悲伤汉堡包采纳,获得10
刚刚
刚刚
刚刚
1秒前
大模型的应助被007kl采纳,获得10
1秒前
1秒前
pojian完成签到,获得积分10
2秒前
星空_发布了新的文献求助10
2秒前
老迟到的惜灵完成签到 ,获得积分10
3秒前
张教授完成签到 ,获得积分10
3秒前
叮咚jingle完成签到,获得积分10
3秒前
鲸落发布了新的文献求助10
3秒前
3秒前
SHMILY414完成签到,获得积分10
4秒前
领导范儿的应助被巴扎嘿采纳,获得10
4秒前
orixero的应助被考槃在涧采纳,获得10
4秒前
冷酷太清完成签到,获得积分10
5秒前
5秒前
Hello的应助被re6irth采纳,获得50
5秒前
BAEKHYUN发布了新的文献求助10
5秒前
5秒前
deli完成签到,获得积分10
6秒前
6秒前
Orange的应助被贲耷采纳,获得10
7秒前
ly完成签到 ,获得积分10
7秒前
四月发布了新的文献求助10
7秒前
7秒前
奋斗晓曼的应助被linda采纳,获得10
8秒前
8秒前
lykkk发布了新的文献求助10
8秒前
典雅发布了新的文献求助10
8秒前
9秒前
9秒前
小晴天完成签到,获得积分10
9秒前
鸟窝的应助被ButtcherFly采纳,获得10
9秒前
9秒前
10秒前
10秒前
10秒前
ly关注了科研通微信公众号
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174837
求助须知:如何正确求助?哪些是违规求助? 9566670
关于积分的说明 21788267
捐赠科研通 7768976
什么是DOI,文献DOI怎么找? 3431794
关于科研通互助平台的介绍 2556021
邀请新用户注册赠送积分活动 2477152